Home WORLD-NEWS China approves AstraZeneca’s lung cancer drug

China approves AstraZeneca’s lung cancer drug


China has approved AstraZeneca drug, Imfinzi, to treat an aggressive form of lung cancer in adults, the group said Monday, as a boost to its efforts to tackle the disease.
The drug’s use with chemotherapy for adult patients with extensive stage small cell lung cancer (SCLC) has been approved by China’s National Medical Products Administration, the Anglo-Swedish drugmaker said.
SCLC is an aggressive form of lung cancer that typically recurs and progresses despite a response to chemotherapy. Only about 3% of those with advanced stage disease live more than five years after diagnosis.
China’s approval came after positive results from a late-stage study showing that the drug, when used with chemotherapy, helped improve patients’ overall survival compared to chemotherapy alone. Results from a local trial also matched global results, AstraZeneca said.
The drugmaker is also trying to catch up with Swiss rival Roche, whose Tecentriq has been approved for expanded SCLC in China and many other countries.
AstraZeneca’s lung cancer portfolio includes a range of drugs, including Imfinzi, which was approved last year in the United States and the European Union for expanded-stage SCLC.
Imfinzi, which enables the immune system to track down and attack certain cancer cells, has already been approved in many countries as a treatment for the more common non-small cell lung cancer.
Lung cancer is responsible for about a fifth of all cancer deaths and is the leading cause of cancer deaths in both men and women.



Please enter your comment!
Please enter your name here